Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer

被引：2
|
作者：
Zhu, Xiaolin [1 ]
Koshkin, Vadim S. [1 ]
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
MED | 2024年 / 5卷 / 02期
关键词：
D O I：
10.1016/j.medj.2023.11.010
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Treatment options for patients with metastatic urothelial carcinoma ineligible for cisplatin-based chemotherapy have historically been limited. O'Donnell et al. recently reported the results of EV-103 Cohort K,(1) leading to accelerated approval of enfortumab vedotin and pembrolizumab for cisplatin-ineligible patients and raising additional questions of how to best utilize this effective regimen.
引用
收藏
页码：106 / 108
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
    Li, Andong
    Wu, Meiyu
    Xie, Ouyang
    Xiang, Heng
    Meng, Kehui
    Tan, Chongqing
    Wang, Long
    Wan, Xiaomin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer
    Niegisch, Guenter
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10): : 944 - 946
  • [3] Pembrolizumab plus enfortumab vedotin in urothelial cancer
    Santoni, Matteo
    Takeshita, Hideki
    Massari, Francesco
    Bamias, Aristotelis
    Cerbone, Linda
    Fiala, Ondrej
    Mollica, Veronica
    Buti, Sebastiano
    Santoni, Angela
    Bellmunt, Joaquim
    NATURE REVIEWS UROLOGY, 2024, 21 (07) : 387 - 388
  • [4] Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Powles, T.
    Valderrama, B. P.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano, D.
    Fornarini, G.
    Li, J. R.
    Guemues, M.
    Mar, N.
    Loriot, Y.
    Flechon, A.
    Duran, I
    Drakaki, A.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (10): : 875 - 888
  • [5] FDA OKs Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02):
  • [6] Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer
    Sternschuss, Michal
    Rosenberg, Jonathan E.
    FUTURE ONCOLOGY, 2025,
  • [7] Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
    Catalano, Martina
    Santoni, Matteo
    Roviello, Giandomenico
    EUROPEAN UROLOGY, 2024, 86 (03) : 283 - 283
  • [8] BUDGET IMPACT ANALYSIS OF PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN AS FIRST-LINE TREATMENT OF CISPLATIN-INELIGIBLE LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN USA
    Lai, Y.
    Guo, H.
    Arku, D.
    Meng, Y.
    Li, H.
    VALUE IN HEALTH, 2023, 26 (06) : S88 - S88
  • [9] Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Hoimes, Christopher J.
    Petrylak, Daniel P.
    Flaig, Thomas W.
    Moon, Helen H.
    Friedlander, Terence W.
    Mar, Nataliya
    McKay, Rana R.
    Srinivas, Sandy
    Gravis, Gwenaelle
    Ramamurthy, Chethan
    Bupathi, Manojkumar
    Bracarda, Sergio
    Wright, Phoebe
    Hepp, Zsolt
    Carret, Anne-Sophie
    Yu, Yao
    Dillon, Ryan
    Kataria, Ritesh
    Beaumont, Jennifer L.
    Purnajo, Intan
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1403 - 1414
  • [10] Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer
    Guarino, Adriana
    Santoni, Matteo
    Catalano, Martina
    Roviello, Giandomenico
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2025, 19
12345